Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHRS NASDAQ:IMVT NASDAQ:MLTX NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$17.25-0.2%$12.72$6.00▼$20.50$897.48M0.96199,816 shs182,633 shsIMVTImmunovant$18.28+2.6%$15.71$12.72▼$34.47$3.13B0.631.22 million shs915,417 shsMLTXMoonLake Immunotherapeutics$54.18+3.2%$43.94$31.42▼$58.26$3.47B1.27386,723 shs571,325 shsPTGXProtagonist Therapeutics$56.44-0.4%$50.79$32.50▼$60.60$3.50B2.26840,003 shs703,829 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research+8.13%+11.69%+35.93%+90.00%+45.66%IMVTImmunovant+1.83%+3.01%+14.98%+17.56%-42.40%MLTXMoonLake Immunotherapeutics+5.74%+8.78%+22.42%+37.02%+4.64%PTGXProtagonist Therapeutics+2.39%+8.32%+3.62%+22.39%+49.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHRSGH Research2.0299 of 5 stars3.51.00.00.02.62.50.0IMVTImmunovant1.3768 of 5 stars3.40.00.00.02.21.70.0MLTXMoonLake Immunotherapeutics1.7438 of 5 stars3.51.00.00.01.62.50.0PTGXProtagonist Therapeutics1.4593 of 5 stars2.51.00.00.03.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHRSGH Research 3.00Buy$32.0085.51% UpsideIMVTImmunovant 2.82Moderate Buy$36.3098.58% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$74.5037.50% UpsidePTGXProtagonist Therapeutics 3.00Buy$66.1017.12% UpsideCurrent Analyst Ratings BreakdownLatest GHRS, PTGX, MLTX, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.006/24/2025GHRSGH ResearchJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$39.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/4/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.006/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.006/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AIMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/APTGXProtagonist Therapeutics$434.43M8.05$4.61 per share12.25$11.33 per share4.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHRSGH Research-$38.96M-$0.79N/AN/AN/AN/A-19.20%-18.40%9/2/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7575.25N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)Latest GHRS, PTGX, MLTX, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.73N/AN/AN/AN/AN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A8/5/2025Q2 2025PTGXProtagonist Therapeutics-$0.53N/AN/AN/A$8.32 millionN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/A5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHRSGH ResearchN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHRSGH ResearchN/A29.7129.71IMVTImmunovantN/A11.1611.16MLTXMoonLake Immunotherapeutics0.1821.1121.11PTGXProtagonist TherapeuticsN/A17.2517.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHRSGH Research56.90%IMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipGHRSGH Research41.60%IMVTImmunovant1.80%MLTXMoonLake Immunotherapeutics12.02%PTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHRSGH Research1052.03 million30.38 millionOptionableIMVTImmunovant120171.07 million167.99 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.32 millionOptionablePTGXProtagonist Therapeutics12061.98 million58.95 millionOptionableGHRS, PTGX, MLTX, and IMVT HeadlinesRecent News About These CompaniesProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Increased by Principal Financial Group Inc.July 12, 2025 | marketbeat.comBrokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $66.10July 12, 2025 | americanbankingnews.comChina Universal Asset Management Co. Ltd. Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 9, 2025 | marketbeat.comNew York State Teachers Retirement System Has $2.27 Million Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 9, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by AnalystsJuly 9, 2025 | marketbeat.comTrek Financial LLC Invests $2.83 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 8, 2025 | marketbeat.comMoody Aldrich Partners LLC Boosts Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 4, 2025 | marketbeat.comIllinois Municipal Retirement Fund Reduces Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 2, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 7.2% - What's Next?July 1, 2025 | marketbeat.comProtagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical StartJuly 1, 2025 | biospace.comBProtagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for ObesityJune 30, 2025 | usatoday.comCan Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?June 30, 2025 | msn.comPTGX Protagonist Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comProtagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development CandidateJune 26, 2025 | accessnewswire.comAProtagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia VeraJune 24, 2025 | msn.comProtagonist Therapeutics’ SWOT analysis: biotech stock poised for growthJune 20, 2025 | investing.comCiti Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs OpportunityJune 20, 2025 | msn.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLCJune 19, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by CitigroupJune 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 17, 2025 | marketbeat.comArturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockJune 12, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGHRS, PTGX, MLTX, and IMVT Company DescriptionsGH Research NASDAQ:GHRS$17.25 -0.04 (-0.23%) Closing price 04:00 PM EasternExtended Trading$17.26 +0.01 (+0.06%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Immunovant NASDAQ:IMVT$18.28 +0.47 (+2.64%) Closing price 04:00 PM EasternExtended Trading$18.10 -0.18 (-0.98%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$54.18 +1.66 (+3.16%) Closing price 04:00 PM EasternExtended Trading$54.59 +0.41 (+0.76%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Protagonist Therapeutics NASDAQ:PTGX$56.44 -0.20 (-0.35%) Closing price 04:00 PM EasternExtended Trading$56.38 -0.06 (-0.11%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
